AlphAIAlphAI — Financial news for AI agents
investing.comAUG 242 min read$SRRK

Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD

Scholar Rock Holding Corp (SRRK) hit a 52-week high of $58.52, up 59% over the past year. The company reported a narrower-than-expected Q2 loss and confirmed its lead drug is on track for a U.S. regulatory decision by September 30. Analysts BMO Capital and H.C. Wainwright maintained positive ratings with price targets of $76.00 and $65.00, respectively.

Original reporting
investing.com
Published Aug 24, 2026, 6:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SRRK
Bullish
medium confidence
Mentioned
$SRRK
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SRRKBullishLow
01

Why it matters

The earnings beat and analyst support may trigger short‑term buying, but the upcoming FDA decision remains the primary catalyst.

02

Market read

Earnings beat provides modest upside; main risk remains FDA approval timeline.

03

What to watch

Potential delays in the FDA review or supply‑chain issues at the new fill‑finish facility could dampen upside.

Relevance 6/10Novelty 5/10Timing: ahead of FDA decision on apitegromab (Sept 30)

Background

Scholar Rock reported a narrower Q2 loss than expected and received reaffirmed buy ratings from BMO Capital and H.C. Wainwright.

Company-level read

Ticker impact

$SRRKBullishMedium confidence
Context

Q2 loss of $0.84 per share beat consensus and analysts reaffirmed buy ratings with higher price targets.

Expected impact

Modest upside of 3‑5% over the next week.

Evidence & confidence

Earnings beat is modest and already priced; analyst upgrades reinforce sentiment but scale is limited.

Market effects

Sector

Biotech sector may see slight lift as a peer advances its pipeline.

Regional

US biotech stocks could see modest buying pressure.

Global

Limited; impact confined to niche biotech investors.

Counterpoint

What could challenge this read

The earnings beat is marginal and may not justify higher valuations; price targets could be overly optimistic.

Key entities

  • company
    Scholar Rock Holding Corp

    Biotech firm developing apitegromab.

  • analyst
    BMO Capital

    Reiterated Outperform rating with $76 target.

  • analyst
    H.C. Wainwright

    Reaffirmed Buy rating with $65 target.

Read at source← All news

Related articles

SEP 18
$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

rttnews.com3 min
SEP 17
$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

insidermonkey.com2 min
SEP 15
$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

gurufocus.com2 min
SEP 15
$SRRKHighAI 9/10

Scholar Rock wins FDA approval for spinal muscle atrophy drug

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.

bostonglobe.com2 min